0001711933--12-312025Q1http://fasb.org/us-gaap/2023#AssetImpairmentChargeshttp://fasb.org/us-gaap/2023#AssetImpairmentChargesP1YP1YP4YP1Y4983693149572122P2Yhttp://fasb.org/us-gaap/2023#OperatingExpenseshttp://fasb.org/us-gaap/2023#OperatingExpenses1false0001711933us-gaap:RetainedEarningsMember2025-03-310001711933us-gaap:AdditionalPaidInCapitalMember2025-03-310001711933us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001711933us-gaap:RetainedEarningsMember2024-12-310001711933us-gaap:AdditionalPaidInCapitalMember2024-12-310001711933us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001711933us-gaap:RetainedEarningsMember2024-03-310001711933us-gaap:AdditionalPaidInCapitalMember2024-03-310001711933us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001711933us-gaap:RetainedEarningsMember2023-12-310001711933us-gaap:AdditionalPaidInCapitalMember2023-12-310001711933us-gaap:CommonStockMember2025-03-310001711933us-gaap:CommonStockMember2024-12-310001711933us-gaap:CommonStockMember2024-03-310001711933us-gaap:CommonStockMember2023-12-310001711933akya:EquityIncentivePlan2015Member2025-03-310001711933akya:EquityIncentivePlan2015Member2025-01-012025-03-310001711933srt:MaximumMemberakya:PiperSandlerAndCo.EquityDistributionAgreementMember2022-11-072022-11-070001711933us-gaap:EMEAMember2025-01-012025-03-310001711933srt:NorthAmericaMember2025-01-012025-03-310001711933srt:AsiaPacificMember2025-01-012025-03-310001711933akya:StandaloneSoftwareProductsMember2025-01-012025-03-310001711933akya:ServiceAndOtherMember2025-01-012025-03-310001711933akya:InstrumentWarrantyMember2025-01-012025-03-310001711933akya:InstrumentsMember2025-01-012025-03-310001711933akya:ConsumablesMember2025-01-012025-03-310001711933us-gaap:EMEAMember2024-01-012024-03-310001711933srt:NorthAmericaMember2024-01-012024-03-310001711933srt:AsiaPacificMember2024-01-012024-03-310001711933akya:StandaloneSoftwareProductsMember2024-01-012024-03-310001711933akya:ServiceAndOtherMember2024-01-012024-03-310001711933akya:InstrumentWarrantyMember2024-01-012024-03-310001711933akya:InstrumentsMember2024-01-012024-03-310001711933akya:ConsumablesMember2024-01-012024-03-3100017119332024-01-012024-09-300001711933srt:OfficerMember2025-01-012025-03-310001711933srt:OfficerMember2024-01-012024-03-310001711933akya:AcrivonAgreementMember2024-10-252024-10-250001711933akya:AcrivonAgreementMember2024-10-012024-12-310001711933akya:AcrivonAgreementMember2023-12-042023-12-040001711933akya:AcrivonAgreementMember2022-06-012022-06-300001711933akya:FacilityNotBeingUsedMember2024-03-310001711933us-gaap:LeaseholdImprovementsMember2025-03-310001711933us-gaap:FurnitureAndFixturesMember2025-03-310001711933us-gaap:ComputerEquipmentMember2025-03-310001711933akya:LaboratoryEquipmentMember2025-03-310001711933us-gaap:LeaseholdImprovementsMember2024-12-310001711933us-gaap:FurnitureAndFixturesMember2024-12-310001711933us-gaap:ComputerEquipmentMember2024-12-310001711933akya:LaboratoryEquipmentMember2024-12-310001711933us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001711933us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001711933us-gaap:RetainedEarningsMember2025-01-012025-03-310001711933us-gaap:RetainedEarningsMember2024-01-012024-03-310001711933akya:MidcapTrustTermLoanAmenment2Member2022-06-012022-06-010001711933akya:MidcapTrustTermLoanAmendment3Member2022-11-070001711933akya:MidcapTrustTermLoanTranche3Member2022-06-010001711933akya:MenloParkCaliforniaMember2024-06-300001711933us-gaap:TrademarksAndTradeNamesMember2025-03-310001711933us-gaap:TechnologyBasedIntangibleAssetsMember2025-03-310001711933us-gaap:SoftwareDevelopmentMember2025-03-310001711933us-gaap:LicensingAgreementsMember2025-03-310001711933us-gaap:CustomerRelationshipsMember2025-03-310001711933us-gaap:TrademarksAndTradeNamesMember2024-12-310001711933us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310001711933us-gaap:SoftwareDevelopmentMember2024-12-310001711933us-gaap:LicensingAgreementsMember2024-12-310001711933us-gaap:CustomerRelationshipsMember2024-12-310001711933us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2025-03-310001711933us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationCurrentMember2025-03-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2025-03-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationCurrentMember2025-03-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2025-03-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationCurrentMember2025-03-310001711933us-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2025-03-310001711933us-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationCurrentMember2025-03-310001711933us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001711933us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2024-12-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2024-12-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2024-12-310001711933us-gaap:FairValueMeasurementsRecurringMemberakya:ContingentConsiderationNonCurrentMember2024-12-310001711933us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001711933akya:CostOfServiceAndOtherMember2025-01-012025-03-310001711933akya:CostOfServiceAndOtherMember2024-01-012024-03-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMember2025-03-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-12-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMember2024-12-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMember2024-03-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMember2023-12-310001711933us-gaap:FairValueMeasurementsRecurringMember2025-01-012025-03-310001711933us-gaap:FairValueMeasurementsRecurringMember2024-01-012024-12-310001711933akya:ContingentConsiderationNonCurrentMember2025-01-012025-03-310001711933us-gaap:RestrictedStockUnitsRSUMember2025-03-310001711933us-gaap:EmployeeStockOptionMember2025-03-310001711933akya:EmployeeStockPurchasePlanMember2025-01-012025-03-310001711933akya:MidcapTrustTermLoanMember2020-10-310001711933akya:QuanterixCorporationMembersrt:MaximumMemberakya:AkoyaBiosciencesIncMemberus-gaap:ConvertibleSubordinatedDebtMember2025-04-280001711933akya:MidcapTrustTermLoanMember2025-03-310001711933akya:MidcapTrustTermLoanMember2024-12-310001711933us-gaap:ServiceMember2025-01-012025-03-310001711933us-gaap:ProductMember2025-01-012025-03-310001711933akya:ArgonautManufacturingServicesMember2025-01-012025-03-310001711933us-gaap:ServiceMember2024-01-012024-03-310001711933us-gaap:ProductMember2024-01-012024-03-310001711933akya:ArgonautManufacturingServicesMember2024-01-012024-03-310001711933us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-03-310001711933srt:NorthAmericaMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-03-310001711933srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-03-310001711933us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-03-310001711933us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-03-310001711933srt:NorthAmericaMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-03-310001711933srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-03-310001711933us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-03-310001711933akya:EmployeeStockPurchasePlanMember2025-03-310001711933akya:EmployeeStockPurchasePlanMember2024-12-310001711933akya:QuanterixShareholdersMemberakya:AkoyaBiosciencesIncMember2025-04-280001711933akya:PiperSandlerAndCo.EquityDistributionAgreementMember2022-11-070001711933akya:EquityIncentivePlan2021Member2025-03-310001711933akya:EquityIncentivePlan2021Member2024-12-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-03-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2025-03-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-03-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2025-03-310001711933us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-03-310001711933us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2025-03-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001711933us-gaap:FairValueMeasurementsRecurringMember2025-03-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-12-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2024-12-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-12-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2024-12-310001711933us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-12-310001711933us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310001711933us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2024-12-310001711933us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001711933us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001711933us-gaap:FairValueMeasurementsRecurringMember2024-12-310001711933us-gaap:PropertyPlantAndEquipmentOtherTypesMember2024-01-012024-03-310001711933akya:RightOfUseMember2024-01-012024-03-310001711933us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001711933us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001711933us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001711933us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001711933us-gaap:OperatingExpenseMember2025-01-012025-03-310001711933us-gaap:OperatingExpenseMember2024-01-012024-03-3100017119332024-03-3100017119332023-12-310001711933us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001711933us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001711933us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001711933us-gaap:CostOfSalesMember2025-01-012025-03-310001711933akya:SingleReportableSegmentMember2025-01-012025-03-310001711933us-gaap:EmployeeStockOptionMember2024-11-192024-11-190001711933us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001711933us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001711933us-gaap:CostOfSalesMember2024-01-012024-03-310001711933akya:SingleReportableSegmentMember2024-01-012024-03-310001711933us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001711933us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001711933akya:PkiMemberus-gaap:LicenseMember2025-03-310001711933akya:PkiMemberus-gaap:LicenseMember2024-12-310001711933srt:OfficerMember2025-03-310001711933akya:ArgonautManufacturingServicesMember2025-03-310001711933srt:OfficerMember2024-12-310001711933akya:ArgonautManufacturingServicesMember2024-12-3100017119332025-04-300001711933akya:EmployeeStockPurchasePlanMember2021-04-082021-04-080001711933us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001711933us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001711933us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001711933akya:PiperSandlerAndCo.EquityDistributionAgreementMember2022-11-072022-11-070001711933akya:PkiMembersrt:MinimumMemberus-gaap:LicenseMember2018-09-300001711933akya:PkiMembersrt:MaximumMemberus-gaap:LicenseMember2018-09-300001711933us-gaap:CommonStockMember2025-01-012025-03-310001711933us-gaap:CommonStockMember2024-01-012024-03-310001711933akya:MidcapTrustTermLoanAmendment3Member2025-01-012025-03-310001711933akya:ArgonautManufacturingServicesMembersrt:MinimumMember2025-03-310001711933akya:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001711933us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001711933akya:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001711933us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001711933akya:MidcapTrustTermLoanAmenment2Member2022-06-010001711933akya:MidcapTrustTermLoanAmendment5Member2024-11-012024-11-300001711933akya:MidcapTrustTermLoanAmendment3Member2022-11-072022-11-070001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMember2025-01-012025-03-310001711933akya:ContingentConsiderationNonCurrentMemberakya:SeriesDRedeemableConvertiblePreferredStockMember2024-01-012024-03-310001711933srt:MinimumMember2025-01-012025-03-310001711933srt:MaximumMember2025-01-012025-03-310001711933akya:MidcapTrustTermLoanAmendment3Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-11-072022-11-070001711933akya:MidcapTrustTermLoanAmenment2Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-06-012022-06-010001711933akya:MidcapTrustTermLoanMemberakya:LondonInterbankOfferedRateMember2020-10-012020-10-310001711933akya:MidcapTrustTermLoanMember2020-10-012020-10-3100017119332024-01-012024-12-3100017119332025-01-012025-03-3100017119332024-01-012024-03-310001711933us-gaap:USTreasurySecuritiesMember2025-03-310001711933us-gaap:DebtSecuritiesMember2025-03-310001711933us-gaap:CashEquivalentsMember2025-03-310001711933us-gaap:USTreasurySecuritiesMember2024-12-310001711933us-gaap:DebtSecuritiesMember2024-12-310001711933us-gaap:CommercialPaperMember2024-12-310001711933us-gaap:CashEquivalentsMember2024-12-310001711933akya:QuanterixCorporationMemberakya:AkoyaBiosciencesIncMember2025-04-280001711933akya:QuanterixShareholdersMemberakya:AkoyaBiosciencesIncMember2025-04-282025-04-280001711933akya:QuanterixCorporationMemberakya:AkoyaBiosciencesIncMember2025-04-282025-04-280001711933akya:QuanterixCorporationMembersrt:MaximumMemberakya:AkoyaBiosciencesIncMemberus-gaap:ConvertibleSubordinatedDebtMember2025-04-282025-04-280001711933akya:QuanterixCorporationMembersrt:MaximumMemberakya:AkoyaBiosciencesIncMember2025-04-282025-04-280001711933akya:EquityIncentivePlan2021Member2021-04-080001711933akya:EmployeeStockPurchasePlanMember2021-04-080001711933akya:MidcapTrustTermLoanMember2025-01-012025-03-310001711933akya:MidcapTrustTermLoanMember2024-01-012024-03-3100017119332025-03-3100017119332024-12-31iso4217:USDxbrli:purexbrli:sharesakya:Voteakya:countryakya:customerakya:regioniso4217:USDxbrli:sharesakya:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 001-40344

Akoya Biosciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware		47-5586242
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

100 Campus Drive, 6th Floor Marlborough, Massachusetts		01752
(Address of principal executive offices)		(Zip Code)

(855) 896-8401

Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00001 per share	AKYA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Number of shares of the registrant’s common shares outstanding at April 30, 2025: 49,875,399

Table of Contents

AKOYA BIOSCIENCES, INC.

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION

Item 1. Financial Statements
Consolidated Balance Sheets at March 31, 2025 (Unaudited) and December 31, 2024		2
Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2025 and 2024		3
Consolidated Statements of Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2025 and 2024		4
Consolidated Statements of Stockholders’ (Deficit) Equity (Unaudited) for the Three Months Ended March 31, 2025 and 2024		5
Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2025 and 2024		6
Notes to Consolidated Financial Statements (Unaudited)		7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		31
Item 3. Quantitative and Qualitative Disclosures About Market Risk		43
Item 4. Controls and Procedures		43

PART II. OTHER INFORMATION

Item 1. Legal Proceedings		43
Item 1A. Risk Factors		43
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		47
Item 3. Defaults Upon Senior Securities		47
Item 4. Mine Safety Disclosures		47
Item 5. Other Information		47
Item 6. Exhibits		49
Signatures		50

Table of Contents

Akoya Biosciences, Inc.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this report other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this report and in other documents we file with the Securities and Exchange Commission (the “SEC”) from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this report represent our views as of the date of this report. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Unless otherwise stated or the context otherwise indicates, references to “Akoya,” “we,” “us,” “our” and similar references refer to Akoya Biosciences, Inc. and its consolidated subsidiary.

This report contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Table of Contents

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)


	March 31, 2025		December 31, 2024
		(unaudited)
Assets
Current assets
Cash and cash equivalents	$	20,357	$	11,779
Marketable securities		7,187		23,261
Accounts receivable, net		11,742		13,779
Inventories, net		22,853		24,321
Prepaid expenses and other current assets		4,073		3,592
Total current assets		66,212		76,732
Property and equipment, net		6,920		7,203
Restricted cash		688		686
Demo inventory, net		1,119		1,336
Intangible assets, net		13,845		14,559
Goodwill		18,262		18,262
Operating lease right of use assets, net		3,859		4,255
Financing lease right of use assets, net		1,307		1,525
Other assets		437		447
Total assets	$	112,649	$	125,005
Liabilities and Stockholders’ (Deficit) Equity
Current liabilities
Accounts payable	$	10,291	$	8,759
Accrued expenses and other current liabilities		11,572		10,848
Current portion of operating lease liabilities		2,708		2,674
Current portion of financing lease liabilities		506		609
Deferred revenue		6,518		6,554
Current portion of long-term debt, net of debt discount		76,487		—
Total current liabilities		108,082		29,444
Deferred revenue, net of current portion		2,782		3,063
Long-term debt, net of current portion and debt discount		—		76,182
Deferred tax liability, net		140		129
Operating lease liabilities, net of current portion		3,406		3,988
Financing lease liabilities, net of current portion		616		693
Contingent consideration liability, net of current portion		3,472		3,871
Other liabilities		40		40
Total liabilities		118,538		117,410
Stockholders’ (deficit) equity:
Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively		—		—
Common Stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2025 and December 31, 2024; 49,836,931 and 49,572,122 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively		2		2
Additional paid in capital		295,198		293,022
Accumulated deficit		(301,088)		(285,436)
Accumulated other comprehensive (loss) income		(1)		7
Total stockholders’ (deficit) equity		(5,889)		7,595
Total liabilities and stockholders’ (deficit) equity	$	112,649	$	125,005

See accompanying notes to consolidated financial statements.

Table of Contents

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(in thousands except share & per share data)


	Three months ended
	March 31,		March 31,
	2025		2024
Revenue:
Product revenue	$	12,032	$	12,140
Service and other revenue		4,607		6,210
Total revenue		16,639		18,350
Cost of goods sold:
Cost of product revenue		4,491		6,723
Cost of service and other revenue		2,277		3,248
Total cost of goods sold		6,768		9,971
Gross profit		9,871		8,379
Operating expenses:
Selling, general and administrative		17,580		19,863
Research and development		5,557		5,554
Change in fair value of contingent consideration		146		179
Impairment		—		2,971
Restructuring		—		1,397
Total operating expenses		23,283		29,964
Loss from operations		(13,412)		(21,585)
Other income (expense):
Interest expense		(2,492)		(2,612)
Interest income		313		937
Other expense, net		(13)		(161)
Loss before provision for income taxes		(15,604)		(23,421)
Provision for income taxes		(48)		(63)
Net loss	$	(15,652)	$	(23,484)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.32)	$	(0.48)
Weighted-average shares outstanding, basic and diluted		49,664,515		49,188,170

See accompanying notes to consolidated financial statements.

Table of Contents

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)

(in thousands)


	Three months ended
	March 31,		March 31,
	2025		2024
Net loss	$	(15,652)	$	(23,484)
Other comprehensive loss:
Unrealized loss on marketable securities		(8)		(16)
Total other comprehensive loss		(8)		(16)
Comprehensive loss	$	(15,660)	$	(23,500)

See accompanying notes to consolidated financial statements.

Table of Contents

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF

STOCKHOLDERS’ (DEFICIT) EQUITY (Unaudited)

(in thousands, except share data)


									Accumulated
					Additional				Other		Total
	Common Stock				Paid in		Accumulated		Comprehensive		Stockholders’
	Shares		Amount		Capital		Deficit		Income (Loss)		Equity (Deficit)
Balance at December 31, 2024	49,572,122	$	2	$	293,022	$	(285,436)	$	7	$	7,595
Exercise of stock options	7,367		—		7		—		—		7
Vesting of restricted stock units	257,442		—		(77)		—		—		(77)
Net loss	—		—		—		(15,652)		—		(15,652)
Other comprehensive loss	—		—		—		—		(8)		(8)
Stock-based compensation	—		—		2,246		—		—		2,246
Balance at March 31, 2025	49,836,931	$	2	$	295,198	$	(301,088)	$	(1)	$	(5,889)


									Accumulated
					Additional				Other		Total
	Common Stock				Paid in		Accumulated		Comprehensive		Stockholders’
	Shares		Amount		Capital		Deficit		Loss		Equity
Balance at December 31, 2023	49,117,738	$	2	$	283,839	$	(230,071)	$	—	$	53,770
Exercise of stock options	65,482		—		36		—		—		36
Vesting of restricted stock units	157,197		—		(149)		—		—		(149)
Net loss	—		—		—		(23,484)		—		(23,484)
Other comprehensive loss	—		—		—		—		(16)		(16)
Stock-based compensation	—		—		2,566		—		—		2,566
Balance at March 31, 2024	49,340,417	$	2	$	286,292	$	(253,555)	$	(16)	$	32,723

See accompanying notes to consolidated financial statements.

Table of Contents

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(in thousands)


	Three months ended
	March 31,		March 31,
	2025		2024
Operating activities
Net loss	$	(15,652)	$	(23,484)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,798		2,051
Non-cash interest expense		305		215
Stock-based compensation expense		2,246		2,566
Deferred taxes		11		37
Change in fair value of contingent consideration		146		179
Credit losses on accounts receivable		55		375
Net accretion of marketable securities		(182)		(545)
Operating lease right of use assets		396		728
Provision for excess and obsolete inventories		517		2,298
Impairment		—		2,971
Changes in operating assets and liabilities:
Accounts receivable, net		1,982		3,146
Prepaid expenses and other assets		(471)		4
Inventories, net		995		(7,310)
Accounts payable		1,532		(1,029)
Accrued expenses and other liabilities		(27)		(2,133)
Operating lease liabilities		(548)		(552)
Deferred revenue		(317)		(341)
Net cash used in operating activities		(7,214)		(20,824)
Investing activities
Purchases of property and equipment		(204)		(810)
Purchases of marketable securities		(3,752)		(48,007)
Maturities of marketable securities		20,000		—
Net cash provided by (used in) investing activities		16,044		(48,817)
Financing activities
Proceeds from stock option exercises		7		36
Settlement of restricted stock units for tax withholding obligations		(77)		(149)
Principal payments on financing leases		(180)		(181)
Payments of deferred offering costs		—		(150)
Net cash used in financing activities		(250)		(444)
Net increase (decrease) in cash, cash equivalents, and restricted cash		8,580		(70,085)
Cash, cash equivalents, and restricted cash at beginning of period		12,465		83,824
Cash, cash equivalents, and restricted cash at end of period	$	21,045	$	13,739
Supplemental disclosures of cash flow information
Cash paid for interest	$	2,122	$	2,243
Cash paid for income taxes	$	—	$	—
Supplemental disclosures of non-cash activities
Purchases of property and equipment included in accounts payable and accrued expenses	$	307	$	84

See accompanying notes to consolidated financial statements.

Table of Contents

AKOYA BIOSCIENCES, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in thousands, except share and per share data)

(1) The company and basis of presentation

Description of business

Akoya Biosciences, Inc. (“Akoya” or the “Company”) is a life sciences technology company, founded on November 13, 2015 as a Delaware corporation with operations based in Marlborough, Massachusetts, delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Spatial biology refers to a rapidly evolving technology that enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through Akoya’s PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software and services, the Company offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

On September 28, 2018, the Company acquired the commercial Quantitative Pathology Solutions (“QPS”) division of Perkin Elmer, Inc. (“PKI”), subsequently known as Revvity, Inc. (“Revvity”), for multiplex immunofluorescence, with the aim of providing consumers with a full suite of end-to-end solutions for high parameter tissue analysis. The QPS technology offers pathology solutions for cancer immunology and immunotherapy research, including advanced multiplex immunochemistry staining kits, multispectral imaging and whole side scanning instruments, and image analysis software. The Company’s combined portfolio of complementary technologies aims to fuel groundbreaking advancements in cancer immunology, immunotherapy, neurology and a wide range of other applications. The Company sells into three main regions across the world: North America, Asia-Pacific (“APAC”), and Europe-Middle East-Africa (“EMEA”).

Principles of consolidation

The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Akoya Biosciences UK Ltd. (“Akoya UK”). All intercompany balances and transactions have been eliminated in consolidation.

Unaudited interim financial information

The accompanying consolidated balance sheet as of March 31, 2025, the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of stockholders’ (deficit) equity for the three months ended March 31, 2025 and 2024, and the consolidated statements of cash flows for the three months ended March 31, 2025 and 2024 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2025, the results of its operations for the three months ended March 31, 2025 and 2024, and cash flows for the three months ended March 31, 2025 and 2024. The financial data and other information disclosed in these notes related to the three months ended March 31, 2025 and 2024 are also unaudited. The results for the three months ended March 31, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025, any other interim periods, or any future year or period. The consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated

Table of Contents

financial statements and the notes thereto for the year ended December 31, 2024 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2025.

Liquidity and going concern

The Company is subject to a number of risks similar to other commercial-stage life sciences companies, including, but not limited to, its ability to develop and achieve market acceptance of its products and potential products, successfully compete with its competitors, protect its proprietary technology, and raise additional capital when and as needed.

At March 31, 2025, the Company had cash, cash equivalents, and marketable securities of $27,544 and an accumulated deficit of $301,088. The Company has incurred losses since its inception and has used cash from operations of $7,214 during the three months ended March 31, 2025. The future success of the Company is dependent on its ability to successfully commercialize its products, successfully launch future products, obtain additional capital, if necessary, and ultimately attain profitable operations. The Company has funded its operations primarily from the issuance and sale of the Company’s equity securities, borrowings under its long-term debt agreement and revenue from its commercial operations. The Company completed its initial public offering of the Company’s common stock in April of 2021 (the “IPO”) and completed a follow-on public offering of the Company’s common stock in June of 2023, as further described in Note 12 – Stockholders’ (deficit) equity. There can be no assurance that additional financings will be available to the Company or that the Company will become profitable.

In the event the merger contemplated under the Amended and Restated Agreement and Plan of Merger between the Company, Quanterix Corporation, and Wellfleet Merger Sub, Inc., which is further discussed in Note 2 – Merger, is not consummated, based on the Company’s current operating plan, the Company does not expect to maintain compliance with certain financial covenants at July 31, 2025 under its debt financing with Midcap Financial Trust (the “Midcap Trust Term Loan”). In such event, the Company would intend to seek a waiver, refinance the outstanding borrowings or otherwise mitigate these concerns with Midcap Financial Trust (“Midcap”) or another lender. There can be no assurance that a waiver will be granted or that the Company will be able to refinance the amounts outstanding, and in such an event, the lender may exercise any and all of its rights and remedies provided for under the Midcap Trust Term Loan.

As a result of these uncertainties, there is substantial doubt about the Company’s ability to continue as a going concern for the next twelve months following the date that these consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

(2) Merger

On April 28, 2025, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with Quanterix Corporation, a Delaware corporation (“Quanterix”), and Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Quanterix (“Merger Sub”), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving such Merger as a wholly owned subsidiary of Quanterix. The Merger Agreement amends and restates in its entirety the Agreement and Plan of Merger (the “Original Merger Agreement”) entered into by the Company, Quanterix and Merger Sub on January 9, 2025. Under the Merger Agreement, the Company and Quanterix have agreed to revise certain terms of the Original Merger Agreement to provide that, at the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.00001 per share, of the Company (the “Akoya Common Stock”) outstanding immediately prior to the Effective Time (other than (x) shares held as of the Effective Time by Quanterix, Merger Sub, any direct or indirect wholly owned subsidiary of Quanterix or the Company or by the Company as treasury shares and (y) shares as to which a holder shall have properly demanded appraisal and not have withdrawn or lost such claim for appraisal (“Dissenting Shares”)) will be converted into the right to receive both: (a) 0.1461 (the “Exchange Ratio”) of a fully paid and nonassessable share of common stock, par value $0.001 per share, of Quanterix ( “Quanterix Common Stock” and the shares so delivered in respect of each share of Akoya Common Stock,

Table of Contents

the “Per Share Stock Consideration”) and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding and; (b) $0.38 in cash, without interest (the “Per Share Cash Consideration” and, together with the Per Share Stock Consideration, the “Per Share Merger Consideration”).

The Merger Agreement also provides that, in connection with the consummation of the Merger, as contemplated by the Merger Agreement, (i) the aggregate number of shares of Quanterix Common Stock to be issued by Quanterix will not exceed 19.99% of the issued and outstanding shares of Quanterix Common Stock immediately prior to the Effective Time and (ii) the aggregate cash consideration to be paid by Quanterix (including cash payable upon vesting of Rollover RSUs (as defined in the Merger Agreement) after the Effective Time) will not exceed $20,000. If any of such limits were to be exceeded, the Exchange Ratio and the Per Share Cash Consideration, as the case may be, would be reduced, with a corresponding increase in the other component (to the extent such increase does not exceed the limitations described in the foregoing sentence).

The Merger Agreement provides that, prior to the Effective Time, the board of directors of the Company will nominate two directors in replacement of two of the existing members of Quanterix’s board of directors (who must be from different classes of directors in Quanterix’s board of directors), who would resign as directors of Quanterix immediately prior to the Effective Time. The remaining members of the board of directors of Quanterix are expected to continue serving in such positions.

The obligation of the Company and Quanterix to consummate the transaction contemplated by the Merger Agreement is subject to the satisfaction or waiver of a number of customary conditions, including: (i) the adoption of the Merger Agreement by the Company’s stockholders; (ii) Quanterix’s registration statement on Form S-4 (File No. 333-284932) having become effective after the filing of any required post-effective amendment as may be necessary in order to reflect the revised terms of the Merger as contemplated in the Merger Agreement, and such registration statement not being subject to any stop order or action by the SEC seeking any stop order; (iii) the waiting period applicable to the Merger under the antitrust laws of the United States having expired or been terminated (which condition has already been satisfied based on the applicable filings made by Quanterix and the Company with respect to the transaction contemplated in the Original Merger Agreement); (iv) the absence of laws or orders restraining the consummation of the Merger; and (v) the submission by Quanterix to Nasdaq of a notification of the shares Quanterix Common Stock to be issued in connection with the Merger.

Each of the Company and Quanterix have made customary representations, warranties and covenants. Consummation of the Merger is subject to certain customary closing conditions.

The Merger Agreement contains customary mutual termination rights for the Company and Quanterix, including (i) if the Merger is not completed by August 31, 2025, (ii) in the event that a governmental authority issues a final order or enacts a law that permanently restrains, enjoins, makes illegal or prohibits the Merger or the other transactions contemplated in the Merger Agreement and (iii) in the event that the stockholders of the Company, at a meeting duly convened (or at any adjournment or postponement thereof), do not vote in favor of the adoption of the Merger Agreement. Each party may also terminate the Merger Agreement if the other party breaches its covenants, obligations, representations or warranties contained in the Merger Agreement in a manner that would result in a failure to satisfy the closing conditions relating to such covenants, obligations, representations or warranties.

Quanterix may also terminate the Merger Agreement (i) if the board of directors of the Company changes its recommendation with respect to the adoption thereof by the the Company’s stockholders and (ii) if the Company materially breaches its obligations in the Merger Agreement with respect to no solicitation or negotiations relating to alternative transactions, as described above. In addition, the Company may terminate the Merger Agreement if the board of directors of the Company authorizes entry into a definitive agreement relating to a Superior Proposal (as defined in the Merger Agreement).

Under the Merger Agreement, the Company will be required to pay a termination fee to Quanterix equal to $2,600 if the Merger Agreement is terminated due to (i) the board of directors of the Company having authorized entry into a definitive agreement relating to a Superior Proposal, (ii) the Company having materially breached its obligations in the Merger Agreement with respect to no solicitation or negotiations relating to alternative transactions, as described above,

Table of Contents

(iii) the board of directors of the Company having changed its recommendation that the Company’s stockholders vote to approve the adoption of the Merger Agreement or (iv) within 12 months of certain termination events, the Company having consummated or entered into a definitive agreement relating to certain alternative transactions (which alternative transaction is consummated).

The transaction is expected to close in the second quarter of 2025, assuming satisfaction of all conditions to the Merger.

On April 2, 2025, the Company entered into a securities purchase agreement (the “Original Securities Purchase Agreement”) with Quanterix, pursuant to which the Company will issue and sell to Quanterix from time to time, in a private placement, one or more convertible promissory notes having an aggregate principal amount of up to $30,000 (the “Convertible Notes”). On April 28, 2025, the Company entered into an Amendment No. 1 (the “SPA Amendment”) to the Original Securities Purchase Agreement (as so amended, the “SPA”) with Quanterix. The SPA Amendment modifies the terms of the SPA to provide that the Company may draw on the Convertible Notes between June 15, 2025 and the earlier of (a) the closing of the transaction contemplated by the Merger Agreement and (b) August 31, 2025 if the Merger Agreement is lawfully terminated pursuant to its terms on or prior to such date; provided, however, that if the closing of the transaction contemplated by the Merger Agreement occurs on or prior to June 15, 2025, the Company may not draw on the Convertible Notes. The remaining terms and conditions of the SPA remain substantially unchanged.

Any Convertible Notes issued under the SPA will mature on the earliest to occur of (i) the 91st day following the earlier of (a) November 1, 2027 and (b) the date that the Company’s indebtedness under the Midcap Trust Term Loan is repaid in full and all commitments under such documents have been terminated and (ii) subject to the terms of the Subordination Agreement (as defined below), any acceleration of the Convertible Notes. Any Convertible Note issued under the SPA will bear interest at a rate per annum equal to the SOFR interest rate plus an applicable margin specified in the Convertible Note to, but excluding, the date of repayment or conversion of the Convertible Note. Interest on the Convertible Notes will be paid in arrears on the first day of each month and on the maturity date of the Convertible Notes. Subject to the terms of the Subordination Agreement, any interest payments will be made exclusively to Quanterix in cash.

If drawn, the Convertible Notes will be convertible at the election of Quanterix during the period beginning on the date, if any, that the Merger Agreement is terminated and ending on the maturity date of the Convertible Notes into shares of common stock, par value $0.00001, of Akoya Common Stock, at a conversion price equal to the product of (i) the exchange ratio set forth in the Merger Agreement, as it may be adjusted pursuant to the terms of the Merger Agreement, and (ii) the VWAP of Quanterix’s common stock for the 10 consecutive trading days ending on the trading day prior to the entry into the Merger Agreement, subject to adjustment.

The Convertible Notes prohibit conversion if it would result in the issuance of more than 19.99% of Akoya Common Stock in the aggregate prior to obtaining stockholder approval. The Convertible Notes will also contain customary anti-dilution provisions to adjust the conversion price from time to time based upon certain issuances of securities by the Company. The SPA contains customary representations and warranties and events of default as well as certain operating covenants applicable to the Company until the closing of the transaction contemplated by the Merger Agreement.

At such time as the Company draws any funds and thereby issues any Convertible Notes, the Company, Quanterix, and Midcap Financial Trust will enter into a subordination agreement (the “Subordination Agreement”), pursuant to which the Company and Quanterix will agree, among other things, that the Convertible Notes will be subordinate to any debt outstanding and obligations owing under the Midcap Trust Term Loan.

Table of Contents

(3) Summary of significant accounting policies

Significant accounting policies

The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC and have not materially changed during the three months ended March 31, 2025.

Revenue recognition

The Company follows ASC 606, Revenue from Contracts with Customers (“ASC 606”).

The Company generates revenue from the sale and installation of instruments, related warranty services, reagents, software (both company-owned and with third parties), and laboratory services. Pursuant to ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services.

To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the customer contract; (ii) identification of the performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.

The Company evaluates all promised goods and services within a customer contract and determines which of those are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract.

Most of the Company’s contracts with customers contain multiple performance obligations (i.e., sale of an instrument and warranty services). For these contracts, the Company accounts for individual performance obligations separately if they are distinct (i.e. capable of being distinct and separable from other promises in the contract). The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.

In order to determine the stand-alone selling price, the Company conducts a periodic analysis to determine whether various goods or services have an observable stand-alone selling price as well as to identify significant changes to current stand-alone selling prices. If the Company does not have an observable stand-alone selling price for a particular good or service, then the stand-alone selling price for that particular good or service is estimated using an approach that maximizes the use of observable inputs. The Company’s process for determining stand-alone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. The Company believes that this method results in an estimate that represents the price the Company would charge for the product offerings if they were sold separately.

Taxes, such as sales, value-added and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales.

Table of Contents

Product Revenue

Product revenue is generated by the sale of instruments and consumable reagents predominantly through the Company’s direct sales force in the United States and in geographic regions outside the United States. The Company generally does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers. When an instrument is purchased by a customer, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer). Revenue from the sale of consumables is recognized upon shipment to the customer. The Company’s perpetual software licenses generally have significant stand-alone functionality to the customer upon delivery and are considered to be functional intellectual property. The Company’s perpetual software licenses are considered distinct performance obligations, and revenue allocated to the software license is typically recognized upon provision of the license/software code to the customer (i.e., when the software is available for access and download by the customer).

Service and Other Revenue

Product sales of instruments include a service-based warranty typically for one year following the installation of the purchased instrument, and in many cases an extended warranty which generally have terms ranging from one to four additional years. These are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After completion of the service period, customers have an option to renew or extend the warranty services, typically for additional one-year periods in exchange for additional consideration. The extended warranties are also service-based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended warranty performance obligation on a straight-line basis over the service delivery period. Revenue from separately charged installation services is recognized upon completion of the installation process. Additionally, the Company provides laboratory services, in which revenue is recognized as services are performed. For laboratory services, the Company generally uses the output method to measure the extent of progress towards completion of the performance obligation. For companion diagnostic development, the Company generally uses the cost-to-cost approach to measure the extent of progress towards completion of the performance obligation because the Company believes it best depicts the transfer of assets to the customer. Under the output method, the extent of progress towards completion is measured based on the value of the services transferred to date relative to the remaining services promised under the contract. Under the cost-to-cost measure approach, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenues are recorded proportionally as costs are incurred. The Company records shipping and handling billed to customers as service and other revenue and the related costs in cost of service and other revenue in the consolidated statements of operations.

In June 2022, the Company entered into a Companion Diagnostic Agreement (the “Acrivon Agreement”) with Acrivon Therapeutics, Inc. (“Acrivon”) to co-develop, validate, and commercialize Acrivon’s OncoSignature^® test. On December 4, 2023, the Company amended the Acrivon Agreement, which expanded the scope of work and increased total development milestone payments to an aggregate of $17,250. Such amendment was accounted for as a modification to the existing contract. The Company is entitled to be paid through an upfront payment and at the achievement of certain developmental, commercial, and FDA milestones during the development, that could aggregate to $17,850. On October 25, 2024, the Company entered into the Fourth Amendment to the Acrivon Agreement with Acrivon, which added additional milestone payments totaling $3,000. In connection with such amendment, the Company granted a license of certain intellectual property to Acrivon. Such amendment was accounted for as a separate contract, as the Company concluded the contract modification was for additional goods and services that are distinct and at their standalone selling price. The $3,000 of consideration was recognized as point in time revenue in the fourth quarter of 2024. A portion of milestone payments from the Acrivon Agreement have been received from June 2022 through March 31, 2025.

The Acrivon Agreement is in the scope of ASC 606, Revenue from Contracts with Customers. The Company concluded that the Acrivon Agreement contains one performance obligation for certain development services, since the underlying elements are inputs to a single development service and are not distinct within the context of the contract. Additional development services in the Acrivon Agreement were deemed to be an option, due to certain contingencies

Table of Contents

with significant uncertainty. The Company will recognize revenue over time for the transaction price in an amount proportional to the expenses incurred and the total estimated expenses to satisfy its performance obligation.

The costs incurred by the Company under this arrangement are included as research and development expenses in the Company’s consolidated statements of operations as these costs are related to the development of new services and technology to be owned and offered by the Company.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers by type of products, and between instrument warranty and service and other revenue, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates the Company’s revenue by major source:


	Three months ended
	March 31, 2025		March 31, 2024
Revenue
Product revenue
Instruments	$	5,030	$	4,869
Consumables		6,944		7,001
Standalone software products		58		270
Total product revenue	$	12,032	$	12,140
Service and other revenue
Service and other revenue	$	1,752	$	3,383
Instrument warranty		2,855		2,827
Total service and other revenue	$	4,607	$	6,210
Total revenue	$	16,639	$	18,350

Significant Judgments

The Company’s contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together requires significant judgment. Once the Company determines the performance obligations, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.

Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation in the contract (i.e. instrument, service warranty, installation) would be sold separately. As the first-year warranty for each instrument is embedded in the instrument price, the amount allocated to the first-year warranty has been determined based on the separately identifiable price of the Company’s extended warranty offering when it is sold on a renewal basis.

If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and the expected costs and margin related to the performance obligations. Contracts in which only one performance obligation is identified (i.e., consumables and standalone software products) do not require allocation of the transaction price.

Contract Assets and Liabilities

The Company’s contract assets consist of revenues recognized, but not yet invoiced to customers for lab services, companion diagnostic development, and instruments. The Company classifies contract assets in accounts receivable. Contract assets are classified as current or noncurrent based on timing of when the Company expects to invoice the

Table of Contents

customer. The Company recorded $1,831, $4,023, and $1,276 in contract assets at March 31, 2025, December 31, 2024, and December 31, 2023, respectively.

The Company’s contract liabilities consist of upfront payments for service-based warranties on instrument sales, as well as lab services. The Company classifies contract liabilities associated with service based warranties in deferred revenue, and contract liabilities associated with lab services in accrued expenses. Contract liabilities are classified as current or noncurrent based on the timing of when the Company expects to service the warranty, or complete the lab services contract. At March 31, 2025, the Company recorded contract liabilities of $10,740, including $6,518 in deferred revenue, $2,782 in deferred revenue, net of current portion, and $1,440 in accrued expenses. At December 31, 2024, the Company recorded contract liabilities of $10,581, including $6,554 in deferred revenue, $3,063 in deferred revenue, net of current portion, and $964 in accrued expenses. At December 31, 2023, the Company recorded contract liabilities of $10,977, including $6,688 in deferred revenue, $3,193 in deferred revenue, net of current portion, and $1,096 in accrued expenses. During the three months ended March 31, 2025 and 2024, the Company recognized $1,770 and $2,723 of revenue, respectively, that was included as a contract liability as of December 31, 2024 and 2023, respectively.

Cost to Obtain and Fulfill a Contract

Under ASC 606, the Company is required to capitalize certain costs to obtain customer contracts and costs to fulfill customer contracts. These costs are required to be amortized to expense on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates, compared to previously being expensed as incurred. As a practical expedient, the Company recognizes any incremental costs to obtain a contract as an expense when incurred if the amortization period of the asset is one year or less. Capitalizable costs to obtain contracts, such as commissions, and costs to fulfill customer contracts were determined to be immaterial for the three months ended March 31, 2025 and 2024.

Stock-based compensation

The Company records stock-based compensation for awards granted to employees, non-employees, and to members of the Board of Directors of the Company (the “Board”) for their services on the Board based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period, which is generally four years.

The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company-specific historical and implied volatility, the Company bases its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded, in combination with the Company’s historical volatility. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the Company’s and the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price becomes available. The risk-free interest rate is determined by reference to the U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of common stock; therefore, the expected dividend yield is assumed to be zero.

For restricted stock units (“RSUs”) issued under the Company’s stock-based compensation plans, the fair value of each grant is calculated based on the Company’s stock price on the date of grant.

Table of Contents

The Company has elected to account for forfeitures as they occur; any compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition will be reversed in the period of the forfeiture.

Refer to Note 13 – Stock compensation plans for further details on the Company’s stock-based compensation plans.

Net loss per share attributable to common stockholders

Basic and diluted net loss per common share outstanding is determined by dividing net loss by the weighted average common shares outstanding during the period. For purposes of the diluted net loss per share calculations, stock options, and unvested restricted stock units, are considered to be potentially dilutive securities, but are excluded from the diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share were the same for all periods presented.

Comprehensive loss

Components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and other comprehensive loss are reported net of any related tax effect to arrive at comprehensive loss. Comprehensive loss includes net loss as well as other changes in stockholders’ (deficit) equity that result from transactions and economic events other than those with stockholders which for the three months ended March 31, 2025 and 2024 consist of unrealized loss on marketable securities.

Marketable securities

Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. Short-term marketable securities mature within one year from the balance sheet date while long-term marketable securities mature after one year. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive loss as a separate component of stockholders’ equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are reflected as a component of interest income. Interest on securities sold is determined based on the specific identification method and reflected as interest income. Any realized gains or losses on the sale of investment are reflected as realized (loss) gain on investments.

Recent accounting standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is considered to be an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to avail itself of this extended transition period and, as a result, the Company will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

Recently issued but not yet adopted accounting standards

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update enhances income tax disclosure requirements by requiring public entities to provide additional information in its tax rate reconciliation and additional disclosures about income taxes paid. The update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance and the amendments in this update

Table of Contents

should be applied prospectively, but entities have the option to apply it retrospectively. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 is effective for public business entities for annual periods beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of this standard on its disclosure of consolidated statement of operations.

(4) Significant risks and uncertainties including business and credit concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, marketable securities, and receivables. The Company’s cash equivalents are held by large, credit worthy financial institutions. Marketable securities consist of short-term investments. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks generally exceed federally insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for credit losses. The allowance for credit losses is developed using historical collection experience, current and future economic and market conditions, and a review of the status of customers’ accounts receivable. The Company had an allowance for credit losses of $1,015 and $960 at March 31, 2025 and December 31, 2024, respectively.

For the three months ended March 31, 2025 and 2024, no single customer accounted for more than 10% of revenue. One customer accounted for 13% and 27% of accounts receivable at March 31, 2025 and December 31, 2024, respectively.

Table of Contents

(5) Fair value of financial instruments

The Company measures the following financial liabilities at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented.

The following tables set forth the Company’s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of March 31, 2025 and December 31, 2024:


			Quoted Prices
			in Active		Significant
			Markets for		Other		Significant
	Balance at		Identical		Observable		Unobservable
	March 31,		Assets		Inputs		Inputs
	2025		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash equivalents	$	18,073	$	18,073	$	—	$	—
U.S Treasury securities		7,187		—		7,187		—
Total Assets	$	25,260	$	18,073	$	7,187	$	—

Liabilities:
Contingent consideration – Short term portion	$	513	$	—	$	—	$	513
Contingent consideration – Long term portion		3,472		—		—		3,472
Total Liabilities	$	3,985	$	—	$	—	$	3,985


			Quoted Prices
			in Active		Significant
			Markets for		Other		Significant
	Balance at		Identical		Observable		Unobservable
	December 31,		Assets		Inputs		Inputs
	2024		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash equivalents	$	8,124	$	8,124	$	—	$	—
U.S Treasury securities		20,783		—		20,783		—
Commercial paper		2,478		—		2,478		—
Total Assets	$	31,385	$	8,124	$	23,261	$	—

Liabilities:
Contingent consideration – Long term portion	$	3,871	$	—	$	—	$	3,871
Total Liabilities	$	3,871	$	—	$	—	$	3,871

The following is a summary of cash equivalents and marketable securities as of March 31, 2025 and December 31, 2024:


	March 31, 2025
			Gross		Gross
			Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
Cash equivalents	$	18,073	$	—	$	—	$	18,073
Marketable securities (due in one year or less):
U.S Treasury securities		7,188		—		(1)		7,187
Total marketable securities due in one year or less		7,188		—		(1)		7,187
Total cash equivalents and marketable securities	$	25,261	$	—	$	(1)	$	25,260

Table of Contents


	December 31, 2024
			Gross		Gross
			Unrealized		Unrealized		Estimated
	Cost		Gains		Losses		Fair Value
Cash equivalents	$	8,124	$	—	$	—	$	8,124
Marketable securities (due in one year or less):
U.S Treasury securities		20,776		7		—		20,783
Commercial paper		2,478		—		—		2,478
Total marketable securities due in one year or less		23,254		7		—		23,261
Total cash equivalents and marketable securities	$	31,378	$	7	$	—	$	31,385

The Company held two debt securities at March 31, 2025 classified as marketable securities with original maturity dates greater than three months that were in an unrealized loss position for less than twelve months. The fair market value of these securities was $7,187. The Company evaluated its securities for other-than-temporary impairments based on quantitative and qualitative factors. The Company considered the decline in market value for these securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell these securities, and the Company does not intend to sell these securities before the recovery of their amortized cost basis. Based on its analysis, the Company does not consider these investments to be other-than-temporarily impaired as of March 31, 2025.

The Company had no material realized gains or losses on its available-for-sale securities for the three months ended March 31, 2025 and 2024.

The Company’s recurring fair value measurements using Level 3 inputs relate to the Company’s contingent consideration liability. In those circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through changes in fair value of contingent consideration on the Company’s consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue.

The recurring Level 3 fair value measurements of the Company’s contingent consideration liability include the following significant unobservable inputs:


	Fair Value		Fair Value
	as of		as of
	March 31,		December 31,		Valuation	Unobservable
Contingent Consideration Liability	2025		2024		Technique	Inputs
Revenue-based Payments	$	3,985	$	3,871	Discounted Cash Flow Analysis under the Income Approach	Revenue discount factor, discount rate

Table of Contents

(6) Property and equipment, net

Property and equipment consists of the following:


	Estimated Useful	March 31,		December 31,
	Life (Years)	2025		2024
Furniture and fixtures	7	$	411	$	378
Computers, laptop and peripherals	5		5,200		5,193
Laboratory equipment	5		8,071		7,734
Leasehold improvements	Shorter of the lease life or 7		5,283		5,245
Total property and equipment			18,965		18,550
Less: Accumulated depreciation			(12,045)		(11,347)
Property and equipment, net		$	6,920	$	7,203

There was no impairment related to property and equipment for the three months ended March 31, 2025. For the three months ended March 31, 2024, the Company recorded $902 in impairment related to leasehold improvements, furniture and fixtures, and laboratory equipment associated with its exit of office and laboratory space in Menlo Park, California. Please refer to Note 20 – Leases for further discussion.

Depreciation expense relating to property and equipment charged to operations was $615 and $716 for the three months ended March 31, 2025 and 2024, respectively. Depreciation expense relating to property and equipment charged to cost of sales was $83 and $156 for the three months ended March 31, 2025 and 2024, respectively.

Demo inventory consists of the following:


	Estimated	March 31,		December 31,
	Life (Years)	2025		2024
Demo inventory – gross	3	$	5,074	$	5,152
Less: Accumulated depreciation			(3,955)		(3,816)
Demo inventory, net		$	1,119	$	1,336

Depreciation expense relating to demo equipment charged to operations was $168 and $252 for the three months ended March 31, 2025 and 2024, respectively.

(7) Allowance for credit losses

The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers’ trade accounts receivable. Due to the short-term nature of such receivables, the estimated accounts receivable that may not be collected is based on aging of the accounts receivable balances.

The Company evaluates contract terms and conditions, country, and political risk, and may require prepayment to mitigate risk of loss. Specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The Company monitors changes to the receivables balance on a timely basis, and balances are written off as they are determined to be uncollectable after all collection efforts have been exhausted.

As of March 31, 2025, the Company’s accounts receivable balance was $11,742, net of $1,015 of allowance for credit losses. The following table provides a roll-forward of the allowance for credit losses for the three months ended

Table of Contents

March 31, 2025 that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected.


Balance as of December 31, 2024	$	960
Change in provision		55
Balance as of March 31, 2025	$	1,015

The following table provides a roll-forward of the allowance for credit losses for the three months ended March 31, 2024 that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected.


Balance as of December 31, 2023	$	45
Change in provision		375
Balance as of March 31, 2024	$	420

(8) Inventories, net

Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, direct labor and manufacturing overhead, using the average cost method. The Company analyzes its inventory levels on each reporting date for excess and obsolete inventory. The Company’s analysis requires judgment and is based on factors including, but not limited to, recent historical activity, anticipated or forecasted demand for its products, and market conditions. The Company writes down any excess and obsolete inventories to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale within the cost of goods sold in the consolidated statements of operations.

Inventories, net consisted of the following:


	March 31,		December 31,
	2025		2024
Raw materials	$	3,415	$	3,510
Finished goods		19,438		20,811
Total inventories, net	$	22,853	$	24,321

(9) Intangible assets

Intangible assets as of March 31, 2025 are summarized as follows:


				Accumulated			Useful Life
	Cost			Amortization		Net	(in years)
Customer relationships	$	11,800	$	(5,120)	$	6,680	15
Developed technology		8,300		(4,500)		3,800	12
Licenses		213		(188)		25	15
Trade names and trademarks		6,300		(4,412)		1,888	12
Capitalized software		3,377		(1,925)		1,452	5
Total intangible assets	$	29,990	$	(16,145)	$	13,845

Table of Contents

Intangible assets as of December 31, 2024 are summarized as follows:


				Accumulated			Useful Life
	Cost			Amortization		Net	(in years)
Customer relationships	$	11,800	$	(4,921)	$	6,879	15
Developed technology		8,300		(4,327)		3,973	12
Licenses		213		(187)		26	15
Trade names and trademarks		6,300		(4,205)		2,095	12
Capitalized software		3,377		(1,791)		1,586	5
Total intangible assets	$	29,990	$	(15,431)	$	14,559

Total amortization expense was $714 and $713 for the three months ended March 31, 2025 and 2024, respectively.

As of March 31, 2025, the amortization expense related to identifiable intangible assets in future periods is expected to be as follows:


2025 remaining	$	2,139
2026		2,822
2027		1,956
2028		1,761
2029		1,608
Thereafter		3,559
Total	$	13,845

(10) Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:


	March 31,		December 31,
	2025		2024
Payroll and compensation	$	3,051	$	4,414
Current portion of contingent consideration		1,926		1,382
Inventory purchases		77		319
Customer deposits		1,068		964
Accrued interest		726		741
Accrued legal		2,794		1,369
Other accrued expenses		1,930		1,659
Total accrued expenses and other current liabilities	$	11,572	$	10,848

(11) Debt

Term Loan Agreements

In October 2020, the Company entered into the Midcap Trust Term Loan with Midcap Financial Trust, for a $37,500 credit facility, consisting of a senior, secured term loan. The Company received $32,500 in aggregate proceeds as a result of the debt financing.

The Midcap Trust Term Loan initially provided for an interest only term for 36 months followed by 24 months of straight-line amortization. Interest on the outstanding balance of the Midcap Trust Term Loan was originally to be payable monthly in arrears at an annual rate of one-month LIBOR plus 6.35%, subject to a LIBOR floor of 1.50%. Under the original terms of the loan, at the time of final payment, the Company would be required to pay Midcap Financial Trust a final payment fee of 5.00% of the amount borrowed under the Midcap Trust Term Loan. Additionally, the original terms of the Midcap Trust Term Loan provided that if the loan was prepaid prior to the end of the term, the Company would be required to pay to Midcap Financial Trust a fee as compensation for the costs of being prepared to

Table of Contents

make funds available in an amount determined by multiplying the amount being prepaid by (i) three percent (3.00%) in the first year, two percent, (2.00%) in the second year and one percent (1.00%) in the third year and thereafter.

On March 21, 2022, the Company entered into Amendment No. 1 to the Midcap Trust Term Loan, which amended certain provisions to permit certain additional debt and capital leases.

On June 1, 2022, the Company entered into Amendment No. 2 (“Amendment No. 2”) to the Midcap Trust Term Loan, which permitted the draw of a second tranche of $10,000, and a third tranche of $10,000, which were drawn on June 1, 2022, and September 30, 2022, respectively. Amendment No. 2 also delayed the amortization start dates for the outstanding loan amounts from November 1, 2023 until April 1, 2025, at which point the Company would be required to repay the principal amounts in seven equal monthly installments until the maturity date. Finally, Amendment No. 2 amended the interest rate payable on the term loan to apply an interest rate equal to the Secured Overnight Financing Rate (“SOFR”) rate (with a floor of 1.61448%) plus 6.35%. Substantially all other terms and conditions, and covenants of the credit agreement remained unchanged. In connection with Amendment No. 2, the Company agreed to pay a $75 commitment fee as well as a 0.25% fee upon the funding of each of the second tranche and third tranche amounts. The Company accounted for Amendment No. 2 as a modification pursuant to ASC 470-50.

On November 7, 2022, the Company entered into Amendment No. 3 (“Amendment No. 3”) to the Midcap Trust Term Loan, which permitted the draw of two additional tranches, each totaling $11,250, which were drawn on November 7, 2022, and December 22, 2023, respectively. Amendment No. 3 also delayed the amortization start dates for the outstanding loan amounts from April 1, 2025 until December 1, 2025 (subject to further extension upon certain conditions), at which point the Company would be required to repay the principal amounts in equal monthly installments until the new maturity date of November 1, 2027, which was extended pursuant to Amendment No. 3. In addition, Amendment No. 3 amended the interest rate payable on the term loan to apply an interest rate equal to the SOFR rate (with a floor of 2.50%) plus 6.80%, and reset the call protection to begin as of November 7, 2025. Finally, Amendment No. 3 provided for a commitment fee of $74 that was paid on November 7, 2022 on the new tranche amounts and an exit fee of 4.75%. As part of Amendment No. 3, the Company paid $779 for the accrued amount of the final payment fee. Substantially all other terms and conditions, and covenants of the credit agreement remained unchanged. The Company accounted for Amendment No. 3 as a modification pursuant to ASC 470-50.

In July 2024, the Company entered into Amendment No. 4 (“Amendment No. 4”) to the Midcap Trust Term Loan, which amended certain affirmative financial covenants.

In November 2024, the Company entered into Amendment No. 5 (“Amendment No. 5”) to the Midcap Trust Term Loan, effective as of September 30, 2024, which amended certain affirmative financial covenants. Amendment No. 5 also extended the interest only period from December 1, 2025 until March 1, 2026 (subject to further extension upon certain conditions), at which point the Company must repay the principal amounts in equal monthly installments until the maturity date of November 1, 2027. Finally, Amendment No. 5 increased the exit fee from 4.75% to 6.25%. The Company accounted for Amendment No. 5 as a modification pursuant to ASC 470-50.

On May 12, 2025, the Company entered into Amendment No. 6 (“Amendment No. 6”), pursuant to which, among other things, Midcap Financial Trust, as agent, waived existing events of default as of March 31, 2025 and through the date of Amendment No. 6 and the parties amended certain affirmative financial covenants. Additionally, Amendment No. 6 includes certain additional restrictive covenants, including amending or modifying the Merger Agreement which is reasonably expected to be materially adverse to Midcap’s interest. Substantially all other term and conditions, and covenants of the Midcap Trust Term Loan remain unchanged.

The Company was not in compliance with certain covenants at March 31, 2025 under the Midcap Trust Term Loan. As of the date of this Quarterly Report on Form 10-Q, after giving effect to Amendment No. 6, the Company is in compliance with all covenants under the Midcap Trust Term Loan as of March 31, 2025 and through the date these consolidated financial statements were issued.

The interest rate was 11.24% at March 31, 2025. A final payment fee of $4,688 is due upon the earlier to occur of the maturity date, or prepayment of such borrowings.

Table of Contents

Given that the Company does not expect to maintain compliance with certain financial covenants under the Midcap Trust Term Loan at July 31, 2025 in the event the Merger is not consummated, the Company has classified the Midcap Trust Loan as a current liability in the consolidated balance sheet as of March 31, 2025.

For the three months ended March 31, 2025 and 2024, the Company recorded $276 and $186, respectively, related to the amortization of the final payment fee associated with the Midcap Trust Term Loan.

Debt consists of the following:


	March 31,		December 31,
	2025		2024
Midcap Trust Term Loan	$	75,000	$	75,000
Unamortized debt discount		(302)		(331)
Accretion of final fee		1,789		1,513
Total debt, net		76,487		76,182
Less amount included as short-term		(76,487)		—
Long-term debt, net	$	—	$	76,182

(12) Stockholder’s (deficit) equity

The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 500,000,000 shares of common stock, $0.00001 par value per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share. Each share of the Company’s common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board, subject to the prior rights of holders of all classes of stock outstanding. As of March 31, 2025 and December 31, 2024, a total of 49,836,931 and 49,572,122 shares of common stock were issued and outstanding, respectively, and 13,139,590 and 10,925,793 shares of common stock were reserved for issuance upon the exercise of stock options and vesting of restricted stock, respectively, including 5,731,276, and 3,191,674, respectively, of shares available for issuance under the 2021 Equity Incentive Plan.

On November 7, 2022, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.00001 per share (the “Common Stock”), having an aggregate offering price of up to $50,000 through Piper Sandler as its sales agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Sandler may sell the shares by methods deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made through The Nasdaq Global Select Market (“Nasdaq”), on any other existing trading market for the Common Stock, to or through a market maker, or, if expressly authorized by the Company, in privately negotiated transactions. The Company or Piper Sandler may terminate the Equity Distribution Agreement upon notice to the other party and subject to other conditions. The Company will pay Piper Sandler a commission equal to 3.0% of the gross proceeds of any Common Stock sold through Piper Sandler under the Equity Distribution Agreement and has provided Piper Sandler with customary indemnification rights. As of March 31, 2025 and December 31, 2024, the Company has not sold any shares of common stock under the ATM program.

Issuance costs incurred related to the Equity Distribution Agreement are classified as current assets on the consolidated balance sheet at March 31, 2025 and December 31, 2024.

Table of Contents

(13) Stock compensation plans

2021 Equity Incentive Plan

On March 24, 2021, the Board, and on April 8, 2021, the Company’s stockholders, approved and adopted the 2021 Equity Incentive Award Plan (the “2021 Plan”). The 2021 Plan became effective immediately prior to the closing of the IPO. Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards to individuals who are then employees, officers, directors or consultants of the Company. A total of 1,727,953 shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”) subject to outstanding awards as of the effective date of the 2021 Plan that are subsequently canceled, forfeited or repurchased by the Company were added to the shares reserved under the 2021 Plan. In addition, the number of shares of common stock available for issuance under the 2021 Plan will be automatically increased on the first day of each calendar year during the term of the 2021 Plan, beginning with January 1, 2022 and ending with January 1, 2030, by an amount equal to 5% of the outstanding number of shares of the Company’s common stock on December 31st of the preceding calendar year or such lesser amount as determined by the Board.

2015 Equity Incentive Plan

The 2015 Plan was established for granting stock incentive awards to directors, officers, employees and consultants to the Company. The 2015 Plan provided for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units as determined by the Board. Under the 2015 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the Board, expired no later than 10 years from the date of grant, and vested over various periods not exceeding four years. While no shares are available for future issuance under the 2015 Plan, it continues to govern outstanding equity awards granted thereunder.

Stock Options

During the three months ended March 31, 2025, no options were granted by the Company. During the three months ended March 31, 2024, the Company granted options with an aggregate fair value of $2,709, which are being recorded as compensation expense over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The valuation model for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term (weighted-average period of time that the options granted are expected to be outstanding), volatility of the Company’s common stock and an assumed-risk-free interest rate.

During the three months ended March 31, 2024, the Company granted options to purchase 730,000 shares of common stock at a weighted average fair value of $3.71 per share and a weighted average exercise price of $5.35 per share. For the three months ended March 31, 2024, the fair values were estimated using the Black-Scholes valuation model using the following weighted-average assumptions:


	Three months ended
	March 31,
	2024
Weighted-average risk-free interest rate	4.3	%
Expected dividend yield	—	%
Expected volatility	75.7	%
Expected term	6.1 years

Restricted Stock Units

During the three months ended March 31, 2025 and 2024, the Company granted RSUs with an aggregate fair value of $199 and $5,482, respectively, which are being recorded as compensation expense over the requisite service period.

Table of Contents

The fair value of each grant is calculated based on the Company’s stock price on the date of grant. During the three months ended March 31, 2025, the Company granted 93,092 RSUs at a weighted average fair value of $2.14 per share. During the three months ended March 31, 2024, the Company granted 1,025,951 RSUs at a weighted average fair value of $5.34 per share.

Stock-Based Compensation

Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows:


	Three months ended
	March 31,
	2025		2024
Cost of goods sold	$	82	$	74
Selling, general and administrative		1,769		2,140
Research and development		395		352
Total stock-based compensation	$	2,246	$	2,566

On November 19, 2024, the Board approved a stock option repricing wherein the exercise price of each Eligible Option was reduced to the price of the Company’s common stock as of the market close on November 19, 2024, or $2.16 per share. "Eligible Option" is defined as all outstanding stock options to acquire shares of the Company’s common stock that were issued to active employees of the Company who hold the title of Senior Vice President or below (not a non-employee member of the Board or a consultant) as of November 19, 2024, in which the original exercise price is above the closing price as of November 19, 2024. All outstanding options remain outstanding in accordance with their current terms and conditions. Such repricing is contingent upon the earlier of one year of service, or through November 19, 2025, or a change in control. The stock option repricing resulted in incremental stock-based compensation expense of $830, which will be recognized over a weighted average period of 4.7 years. Incremental stock-based compensation expense of $157 was recognized in the first quarter of 2025.

As of March 31, 2025, there was $4,707 of total unrecognized compensation cost related to unvested stock options that is expected to be recognized over a remaining weighted-average period of 2.0 years.

As of March 31, 2025, there was $8,473 of total unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a remaining weighted-average period of 2.2 years.

(14) Employee stock purchase plan

On March 24, 2021, the Board and on April 8, 2021, the Company’s stockholders approved and adopted the 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP became effective in connection with the closing of the Company’s IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 172,795 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2022 and ending with January 1, 2030, by an amount equal to 0.5% of the outstanding number of shares of the Company’s common stock on December 31st of the preceding calendar year or such lesser amount as determined by the Board. No shares have been issued under the ESPP at March 31, 2025 and December 31, 2024, respectively.

(15) Income taxes

During the three months ended March 31, 2025 and 2024, the Company recorded a tax provision of $48 and $63, respectively. The tax provision consists primarily of foreign income taxes and state taxes in the United States. The provision differs from the U.S. federal statutory rate of 21% primarily due to the full valuation allowance recorded against the U.S. deferred tax assets, including the current year to date losses. The Company maintains a valuation

Table of Contents

allowance against its U.S. deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.

(16) Commitments and contingencies

License Agreements

In September 2018, in connection with the acquisition of the QPS division of PKI (subsequently known as Revvity), the Company entered into a License Agreement with PKI, pursuant to which PKI granted the Company an exclusive, nontransferable, sublicensable license under certain patent rights to make, use, import and commercialize QPS products and services. The Company is required to pay royalties on net sales of products and services that are covered by patent rights under the agreement at a rate ranging from 1.0% to 7.0%. As of the acquisition date, the Company accounted for the future potential royalty payments as contingent consideration. This contingent consideration is subject to remeasurement. The Company recorded approximately $513 and $1,382 of accrued royalties for projected net sales in 2025, and actual net sales in 2024, as of March 31, 2025 and December 31, 2024, respectively. Such amounts are payable in the first quarter of 2026 and 2025, respectively.

Changes in the fair value of the Company’s long-term portion of the contingent consideration liability during the three months ended March 31, 2025 and 2024 were as follows:


Balance as of December 31, 2024	$	3,871
Reclassification of FY 2025 payment to accrued expenses		(545)
Change in contingent consideration value		146
Balance as of March 31, 2025	$	3,472


Balance as of December 31, 2023	$	5,765
Reclassification of FY 2024 payment to accrued expenses		(1,929)
Change in contingent consideration value		179
Balance as of March 31, 2024	$	4,015

(17) Net loss per share attributable to common stockholders

Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards. Awards granted with performance conditions are excluded from the shares used to compute diluted earnings per share until the performance conditions associated with the awards are met.

The following table sets forth the computation of basic and diluted earnings per common share:


	Three months ended
	March 31,
	2025		2024
Net loss	$	(15,652)	$	(23,484)
Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted		49,664,515		49,188,170
Basic and diluted net loss per common share outstanding	$	(0.32)	$	(0.48)

The Company’s potential dilutive securities, which include stock options, and unvested restricted stock units, have been excluded from the computation of diluted net loss per share attributable to common stockholders whenever the effect of including them would be to reduce the net loss per share. In periods where there is a net loss, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at

Table of Contents

each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	March 31,
	2025	2024
Outstanding stock options	5,250,419	6,290,879
Unvested restricted stock units	2,157,895	2,034,945
Total	7,408,314	8,325,824

(18) Segments

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (the “CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM, the Company’s chief executive officer, reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. The CODM views the Company’s operations and manages its business as a single operating segment. Accordingly, the Company has a single reportable segment structure. The measure of segment assets is reported on the balance sheet as total assets. The Company’s principal operations and decision-making functions are located in the United States.

In accordance with ASC 2023-07, Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures, the following table presents the segment revenue and significant expense categories included within the Company’s segment’s measure of loss for the three months ended March 31, 2025 and 2024:


	Three months ended
	March 31,
($ in thousands)	2025		2024
Revenue		16,639		18,350
Less:
Cost of goods sold, excluding depreciation, amortization, and stock-based compensation		6,615		9,652
Operating expenses - compensation and benefits		9,833		15,013
Operating expenses - outside services		5,493		2,189
Other segment items^(a)		3,920		5,314
Depreciation and right-of-use amortization		1,084		1,338
Amortization of intangibles		714		713
Stock-based compensation		2,246		2,566
Change in fair value of contingent consideration		146		179
Impairment		—		2,971
Interest expense		2,492		2,612
Interest income		(313)		(937)
Other expense, net		13		161
Provision for income taxes		48		63
Net loss	$	(15,652)	$	(23,484)

(a)

Other segment items included in net loss includes insurance, rent and utilities, repairs & maintenance, IT, lab supplies, travel & entertainment, allowance for credit losses, and other overhead expenses.

Table of Contents

The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped:


	Three months ended
	March 31,
	2025		2024
North America	$	10,138	$	10,124
APAC		2,585		3,270
EMEA		3,916		4,956
Total Revenue	$	16,639	$	18,350


	Three months ended
	March 31,
	2025		2024
North America	61	%	55	%
APAC	15	%	18	%
EMEA	24	%	27	%
Total Revenue	100	%	100	%

North America includes the United States and related territories, as well as Canada. APAC also includes Australia. For the three months ended March 30, 2025 and 2024, the Company had no countries outside of the United States with more than 10% of total revenue.

As of March 31, 2025 and December 31, 2024, substantially all of the Company’s long-lived assets are located in the United States.

(19) Related party transactions

Argonaut Manufacturing Services Inc. (“AMS”) is a portfolio company of Telegraph Hill Partners, which holds greater than 5% of the Company’s total outstanding shares. During the three months ended March 31, 2025 and 2024, the Company incurred costs of goods sold of approximately $0 and $1,673, respectively, related to sales of consumables manufactured by and shipped from AMS. During the three months ended March 31, 2025, the Company incurred research and development expenses of approximately $127 with AMS. As of March 31, 2025 and December 31, 2024, the Company had $173 and $581 in accounts payable, respectively, due to AMS.

One of the Company’s officers is a member of the board of directors of a software-as-a-service provider, who provides software development services to the Company, which are utilized for research purposes. During the three months ended March 31, 2025 and 2024, the Company incurred research and development expenses of $295 and $135, respectively, with such provider. As of March 31, 2025 and December 31, 2024, the Company had $178 and $206 in accounts payable, respectively, due to such provider.

(20) Leases

There were no ROU asset or leasehold improvement impairments recorded in the three months ended March 31, 2025.

In the first quarter of 2024, the Company ceased use of its leased facility in Menlo Park, California with the intention to either sublease or exit the vacant space to recover a portion of the total lease costs. The Company’s cease use of its leased facilities required an impairment assessment and the related right-of-use (“ROU”) assets and property and equipment became their own asset group. The impairment analysis evaluated the present value of net cash flows under the original lease and the estimated cash flows under estimated subleases to identify any potential impairment amount. The impairment assessment considered all industry and economic factors such as rental rates, interest rates, and recent real estate activities to estimate the net cash flows analysis and impairment amount.

Table of Contents

The above assessments resulted in the Company recording an impairment charge of $2,971 during the three months ended March 31, 2024, which was recorded in impairment on the consolidated statements of operations. For the three months ended March 31, 2024, impairment charges included $2,069 impairment of ROU assets, and $902 impairment of property and equipment, respectively. After recording impairments for the three months ended March 31, 2024, the carrying value of ROU assets and related property and equipment for the facility not being used was $2,115.

In June 2024, the Company signed a thirty-five month sublease agreement for a portion of its leased facility in Menlo Park, California. In connection with this agreement, the Company received a security deposit totaling $40, which is recorded as a component of long-term liabilities in the consolidated balance sheet. The lease commencement date was July 2024.

The Company is a lessee under operating leases of offices, warehouse space, laboratory space, and auto leases, and financing leases of computer equipment and staining equipment.

Some leases include an option to renew, with renewal terms that can extend the lease term by five years. The exercise of lease renewal options is at the Company’s sole discretion. None of these options to renew are recognized as part of the Company’s ROU asset or lease liability as of March 31, 2025, as renewal was determined to not be reasonably assured.

The table below summarizes the Company’s lease costs for the three months ended March 31, 2025 and 2024:


		Three months ended March 31,
Lease Costs	Classification	2025		2024
Finance lease cost:
Amortization of right-of-use assets	Cost of service and other revenue	$	70	$	89
Amortization of right-of-use assets	Selling, general and administrative		12		41
Amortization of right-of-use assets	Research and development		136		84
Interest on lease liabilities	Interest expense, net		33		34
Operating lease cost:
Sublease income	Selling, general and administrative		(110)		—
Rent expense	Cost of product revenue		26		28
Rent expense	Selling, general and administrative		498		706
Total lease cost		$	665	$	982

As of March 31, 2025, future minimum commitments under ASC 842 under the Company’s operating leases were as follows:


Maturity of operating lease liabilities	As of March 31, 2025
2025 remaining	$	2,101
2026		2,615
2027		1,104
2028		436
2029		449
Thereafter		113
Total lease payments	$	6,818
Less: discount to lease payments		(704)
Total operating lease liabilities	$	6,114

Table of Contents

As of March 31, 2025, future minimum commitments under ASC 842 under the Company’s financing leases were as follows:


Maturity of financing lease liabilities	As of March 31, 2025
2025 remaining	$	422
2026		430
2027		383
2028		60
Total lease payments	$	1,295
Less: discount to lease payments		(173)
Total financing lease liabilities	$	1,122

The table below summarizes the weighted-average remaining lease term (in years), the weighted-average incremental borrowing rate (in percentages), as well as supplemental cash flow information related to leases for the three months ended March 31, 2025 and 2024:


	Three months ended March 31,
Lease Term, Discount Rates, and Other	2025			2024
Weighted average remaining lease term
Operating leases		2.9	years		3.6	years
Financing leases		2.6	years		3.0	years
Weighted average incremental borrowing rate
Operating leases		7.85	%		7.85	%
Financing leases		11.46	%		9.90	%
Cash payments of amounts included in lease liabilities
Operating cash flows from operating leases	$	670		$	718
Operating cash flows from finance leases		33			34
Financing cash flows from finance leases		180			181

(21) Reduction in force

In January of 2024, the Company initiated a workforce reduction in connection with certain operating expense cost savings initiatives implemented by the Company, including the consolidation of its facilities and the exit of its Menlo Park, California leased facility as discussed in Note 20 – Leases. This workforce reduction was substantially completed by the end of the first quarter of 2024.

During the three months ended March 31, 2024, the Company recorded $1,257 for charges related to this workforce reduction, and $140 of employee and equipment relocation costs associated with the Menlo Park, California exit, respectively, which were recorded in restructuring on the consolidated statements of operations. As of March 31, 2025, none of these workforce reduction charges remain unpaid.

In July 2024, the Company initiated a workforce reduction in connection with certain operating expense cost savings initiatives. This workforce reduction was substantially completed by the end of the third quarter of 2024.

During the three months ended September 30, 2024, the Company recorded $1,690 for charges related to this workforce reduction, which were recorded in restructuring on the consolidated statements of operations. As of March 31, 2025, $19 of these workforce reduction charges remain unpaid.

(22) Subsequent events

The Company has evaluated subsequent events from the consolidated balance sheet date through May 12, 2025, which is the date the consolidated financial statements were issued.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2024 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2025. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those described in our Annual Report on Form 10-K for the year ended December 31, 2024, as referred to in the section titled “Risk Factors” under Part II, Item 1A below. Please also see the section titled “Special note regarding forward looking statements.”

Overview

We are an innovative life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Our mission is to bring context to the world of biology and human health through the power of spatial phenotyping. Spatial phenotyping refers to a rapidly evolving technology that enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through our PhenoCycler and PhenoImager platforms, reagents, software and services, we offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Our spatial biology solutions measure cells and proteins by providing biomarker data in its spatial context while preserving tissue integrity. Biomarkers are objective measures that capture what is happening in a cell or tissue at a given moment. Current genomic and proteomic methods, such as next-generation sequencing (“NGS”), single-cell analysis, flow cytometry and mass spectrometry, are providing meaningful data but require the destruction of the tissue sample for analysis. While valuable and broadly adopted, these approaches allow scientists to analyze the biomarkers and cells that comprise the tissue but do not provide the fundamental information about tissue structure, cellular interactions and the localized measurements of key biomarkers. Furthermore, current non-destructive tissue analysis and histological methods provide some limited spatial information, but they only measure a minimal number of biomarkers at a time and require expert pathologist interpretation. Our platforms address these limitations by providing end-to-end solutions that enable researchers to quantitatively interrogate a large number of biomarkers and cell types across a tissue section at single-cell resolution. The result is a detailed and computable map of the tissue sample that thoroughly captures the underlying tissue dynamics and interactions between key cell types and biomarkers, a process now referred to as spatial phenotyping. We believe that we are the only business with the breadth of platform capabilities that enable researchers to do a deep exploratory and discovery study, and then further advance and scale their research through the translational and clinical phases, leading to a better understanding of human biology, disease progression and response to therapy. We also believe that we are the only spatial biology business that is capable of delivering a menu of clinical in vitro diagnostics tests on our platform for routine diagnostic testing.

We offer complete end-to-end solutions for spatial phenotyping, designed to serve the unique needs of our customers in the discovery, translational and clinical markets. The PhenoCycler is an ultra-high parameter and cost-effective platform ideally suited for discovery high-plex research. The PhenoImager platforms, which includes the Fusion instrument and HT instrument, provide high-throughput scalable solutions with the automation and robustness needed for translational and clinical applications. Furthermore, the PhenoCycler and the PhenoImager Fusion can be integrated into a combined system, the PhenoCycler-Fusion, to enable spatial discovery at scale by providing significant improvements in the speed of the workflow. Our portfolio of products offer seamless and integrated workflow solutions for our customers, including important benefits such as flexible sample types, automated sample processing, scalability, comprehensive data analysis and software solutions and dedicated field and applications support. With these platforms,

Table of Contents

our customers are performing spatial phenotyping to further advance their understanding of diseases such as cancer, neurological and autoimmune disorders, and many other therapeutic areas.

For the three months ended March 31, 2025 and 2024, revenue from North America accounted for approximately 61% and 55% of our revenue, respectively.

We generally outsource the manufacturing of our instruments and certain of our reagents. Design work and prototyping are performed in-house before pilot manufacturing and production are outsourced to third-party contract manufacturers. We use one contract manufacturer to produce our PhenoImager and PhenoCycler instruments, and several suppliers to produce certain of our reagent kits and components. Additionally, we have made investments in our infrastructure to support strategic in-house manufacturing as it relates to our critical and high-complexity proprietary reagents. The contract manufacturers of our systems and reagent kits are located in the United States and Asia. Certain of our suppliers of components and materials are single source suppliers.

As of the date of this Quarterly Report on Form 10-Q, we have financed our operations primarily from the issuance and sale of our equity securities, borrowings under our long-term debt agreement, and revenue from our commercial operations. We have incurred net losses in each period since our inception in 2015. Our net losses were $15.7 million and $23.5 million for the three months ended March 31, 2025 and 2024, respectively. We expect to continue to incur operating losses for the foreseeable future. In the event that the transaction contemplated under the Merger Agreement we have entered into with Quanterix is not consummated, based on our current operating plan, we do not expect to maintain compliance with certain financial covenants at July 31, 2025 under the Midcap Trust Term Loan. In such event, we would intend to seek a waiver, refinance the outstanding borrowings or otherwise mitigate these concerns with Midcap Financial Trust or another lender. There can be no assurance that a waiver will be granted or that we will be able to refinance the amounts outstanding, and in such an event, the lender may exercise any and all of its rights and remedies provided for under the Midcap Trust Term Loan. As a result of these uncertainties, there is substantial doubt about our ability to continue as a going concern for the next twelve months. However, we plan to continue to grow our business while improving results of operations in an effort to achieve cash flow positivity, as we:

●

attract, hire and retain qualified personnel, including in connection with our investments in our infrastructure to support in-house manufacturing;

●

market and sell new and existing solutions and services;

●

invest in processes and infrastructure to scale our business;

●

support research and development to introduce new solutions;

●

expand, protect and defend our intellectual property; and

●

acquire complementary businesses or technologies to support the growth of our business.

Key factors affecting our results of operations and future performance

There are a number of factors that have impacted, and we believe will continue to impact, our business, results of operations and growth. Our ability to successfully address these factors is subject to various risks and uncertainties, including those described under the heading “Risk Factors.”

Our ability to expand our installed base

We are focused on increasing sales of our PhenoCycler and PhenoImager platforms (Fusion and HT) to new and existing customers. Our financial performance has historically been driven by, and will continue to be impacted by, the volume of instrument sales. Additionally, instrument sales are a leading indicator of future recurring revenue from consumables and services. Our operating results and growth prospects will be dependent in part on our ability to increase

Table of Contents

our instrument installed base as we further penetrate existing markets and expand into, or offer new features and solutions that appeal to, new markets.

We believe our market is still evolving and relatively underpenetrated. As spatial biology is further validated through rapid acceleration of peer-reviewed publications and growing adoption by the life sciences research market, we believe we have an opportunity to significantly increase our installed base. We regularly solicit feedback from our customers in order to enhance our solutions and their applications for life sciences research, which we believe will drive increased adoption of our platforms as they better serve our customers’ needs.

Our ability to drive incremental pull through

We believe that expansion of our installed base to new and existing customers will drive an increase in our recurring reagent and instrument service revenue. In addition, as our research and development team identifies and launches new applications and biomarker targets, we expect to increase incremental pull through on our existing and new instrument installed base. Recurring revenue was 59% and 54% of total revenue for the three months ended March 31, 2025 and 2024, respectively. Our recurring revenue as a percentage of total product and service revenue will vary based upon new device placements in the period. As our installed base expands, we expect recurring revenue on an absolute basis to increase and become an increasingly important contributor to our revenue.

Our ability to improve revenue mix and gross margin

Our revenue is primarily derived from sales of our platforms, consumables, software, and services. Our revenue mix will fluctuate from period-to-period, particularly revenue generated from instrument sales. As our installed base grows, we expect consumables and instrument service revenue to constitute a larger percentage of total revenue.

Our margins are higher for those instruments and consumables that we sell directly to customers compared to those sold through distributors.

Future instrument and consumable selling prices and gross margins may fluctuate due to a variety of factors, including the introduction by others of competing products and solutions. We aim to mitigate downward pressure on our average selling prices by increasing the value proposition offered by our instruments and consumables, primarily by expanding the applications for our devices, optimizing the performance of our products, introducing feature enhancements and increasing the quantity and quality of data that can be obtained using our consumables.

Key Business Metrics

We regularly review the number of instrument placements and cumulative instrument placement as key metrics to evaluate our business, measure our performance, identify trends affecting our business, develop financial projections, and make strategic decisions. We believe that these metrics are representative of our current business; however, we anticipate these will change or may be substituted for additional or different metrics as our business grows.

During the three months ended March 31, 2025 and 2024, our instrument placements were as follows:


	Three months ended
	March 31,
	2025	2024
Instrument Placements:	29	30

Our instruments are sold globally to leading biopharma companies and top research institutions and medical centers. Our quarterly instrument placements fluctuate from period-to-period due to the type and size of our customers and their procurement and budgeting cycles. We expect continued fluctuations in our quarterly period-to-period number of instrument placements.

Table of Contents

We believe our instrument placements is an important metric to measure our business because the number of new placements is driven by our ability to secure new customers and to increase adoption of our PhenoCycler and PhenoImager platforms and because it provides insights into anticipated recurring revenue for consumables and instrument services.

Components of results of operations

Revenue

Product Revenue

We generate product revenue from the sale of our instruments, consumables and software products. Instrument sales accounted for 42% and 40% of product revenue for the three months ended March 31, 2025 and 2024, respectively. Consumables revenue accounted for 58% of our product revenue for each of the three months ended March 31, 2025 and 2024.

Our current instrument offerings include our PhenoCycler and PhenoImager platforms. Our sales process with customers is often long and involves multiple levels of approvals. As a result, the revenue for our platforms can vary significantly from period-to-period and has been, and may continue to be, concentrated in a small number of customers in any given period.

We sell our instruments directly to customers and through distributors. Each of our instrument sales drives various streams of recurring revenue comprised of consumable product sales and instrument services.

Service and Other Revenue

We primarily generate service and other revenue from instrument service, which generally consists of sales of extended service contracts, in addition to installation and training, as well as from our laboratory services operations, where we provide sample testing services to customers utilizing our in-house lab operation, and revenue generated from companion diagnostic development.

We offer our customers extended warranty and service plans for our platforms. Our extended warranty and service plans are offered for periods beyond the standard one-year warranty that all customers receive. These extended warranty and service plans generally have fixed fees and terms ranging from one to four additional years. We recognize revenue from the sale of extended warranty and service plans over the respective coverage period, which approximates the service effort provided by us.

We record shipping and handling billed to customers as service and other revenue and the related costs in cost of service and other revenue in the consolidated statement of operations.

We sell our products globally. We sell directly to end customers in North America and we sell through third party distributors and dealers in the APAC region. We sell both directly and through third party distributors in EMEA.

Cost of Goods Sold, Gross Profit and Gross Margin

Product cost of revenue primarily consists of costs for finished goods (both instruments and reagents) produced by our contract manufacturers or in-house, and associated freight, shipping and handling costs for products shipped to customers, salaries and other personnel costs, and other direct costs related to those sales recognized as product revenue in the period. Cost of goods sold for services and other revenue primarily consists of salaries and other personnel costs, travel related to services provided, costs of servicing equipment at customer sites, and all personnel and related costs for our laboratory services operation.

We expect that our cost of goods sold will increase or decrease to the extent that our revenue increases and decreases and depending on the mix of revenue in any specific period.

Table of Contents

Gross profit is calculated as revenue less cost of goods sold. Gross margin is gross profit expressed as a percentage of revenue. Our gross profit in future periods will depend on a variety of factors, including market conditions that may impact our pricing, sales mix among instruments, sales mix changes among consumables, excess and obsolete inventories, costs we pay our contract manufacturers for their services, our cost structure for lab service operations relative to volume, product warranty obligations, and inflationary cost pressures. Our gross profit in future periods will also vary based upon our channel mix and may decrease based upon our distribution channels.

Gross profit was $9.9 million compared to $8.4 million for the three months ended March 31, 2025 and 2024, respectively.

Operating expenses

Research and development. Research and development costs primarily consist of salaries, benefits, engineering/design costs, laboratory supplies, materials expenses for employees and third parties engaged in research and product development, and depreciation of property and equipment and amortization of intangibles. We expense all research and development costs in the period in which they are incurred.

We plan to continue to invest in our research and development efforts to enhance existing products and develop new products. We expect these expenses to vary from period to period as a percentage of revenue.

Selling, general and administrative. Our selling, general and administrative expenses primarily consist of salaries and benefits for employees in our executive, accounting and finance, sales and marketing, operations, legal and human resource functions, professional services fees, such as consulting, audit, tax and legal fees, legal expenses related to intellectual property, general corporate costs, commercial sales functions, marketing, travel expenses, facilities, and IT, as well as depreciation of property and equipment and amortization of intangibles. We expect these expenses to vary from period to period as a percentage of revenue.

Change in fair value of contingent consideration. On September 28, 2018, we acquired substantially all the assets of the QPS division of PKI (subsequently known as Revvity). As part of the acquisition, on September 28, 2018, we entered into a License Agreement with PKI. Under the terms of the License Agreement, we agreed to pay PKI certain royalties as a percentage of future net sales of products and services that are covered by patent rights under the agreement, in exchange for a perpetual license of the right to produce and sell QPS products. As of the acquisition date, we accounted for the future potential royalty payments as contingent consideration. This contingent consideration is subject to remeasurement.

Impairment. Impairment expense primarily consists of charges recorded as a result of exiting the Menlo Park, California facilities. As a result of exiting the facilities, we performed an impairment assessment of our long-lived assets, including operating lease right-of-use assets and property and equipment. A portion of our operating lease right-of-use assets (including related property and equipment) were determined to be impaired as their carrying values exceeded their fair values, and corresponding impairment charges were recorded in the three months ended March 31, 2024.

Restructuring. Restructuring expense primarily consists of charges recorded in connection with our workforce reductions executed in January of 2024.

Other income (expense)

Interest expense. Interest expense consists primarily of interest related to borrowings under our debt obligations.

Interest income. Interest income consists of interest earned on cash, cash equivalents, and marketable securities, and the accretion of discounts from the purchase of marketable securities.

Other expense, net. Other expense, net consists primarily of franchise tax and foreign currency exchange gains and losses.

Table of Contents

Provision for income taxes

Our provision for income taxes consists primarily of foreign taxes and minimal state taxes in the United States. As we expand the scale and scope of our international business activities, any changes in the United States and foreign taxation of such activities may increase our overall provision for income taxes in the future.

Results of operations

The results of operations presented below should be reviewed in conjunction with the consolidated financial statements and notes included elsewhere in the Quarterly Report on Form 10-Q. The following tables set forth our results of operations for the periods presented:


	Three months ended
	March 31,
($ in thousands)	2025		2024
Product revenue	$	12,032	$	12,140
Service and other revenue		4,607		6,210
Total revenue		16,639		18,350
Cost of goods sold:
Cost of product revenue		4,491		6,723
Cost of service and other revenue		2,277		3,248
Total cost of goods sold		6,768		9,971
Gross profit		9,871		8,379
Operating expenses:
Selling, general and administrative		17,580		19,863
Research and development		5,557		5,554
Change in fair value of contingent consideration		146		179
Impairment		—		2,971
Restructuring		—		1,397
Total operating expenses		23,283		29,964
Loss from operations		(13,412)		(21,585)
Other income (expense):
Interest expense		(2,492)		(2,612)
Interest income		313		937
Other expense, net		(13)		(161)
Loss before provision for income taxes		(15,604)		(23,421)
Provision for income taxes		(48)		(63)
Net loss	$	(15,652)	$	(23,484)

Comparison of the three months ended March 31, 2025 and 2024

Revenue


	Three months ended
	March 31,					Change
($ in thousands, except percentages)	2025		2024			Amount	%
Product revenue	$	12,032	$	12,140	$	(108)	(1)	%
Service and other revenue		4,607		6,210		(1,603)	(26)	%
Total revenue	$	16,639	$	18,350	$	(1,711)	(9)	%

Product revenue decreased by $0.1 million, or 1%, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease was primarily driven by a $0.2 million decrease in instrument revenue resulting from 29 new system placements during the three months ended March 31, 2025, compared to 30 new system placements for the three months ended March 31, 2024, offset by a $0.1 million increase in consumable revenue

Table of Contents

resulting from a larger installed base of 1,359 systems as of March 31, 2025, as compared to 1,213 systems as of March 31, 2024.

Service and other revenue decreased by $1.6 million, or 26%, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease was primarily due to a decrease relating to lab services revenue, decreases in revenue generated from companion diagnostic development, and other immaterial changes.

Cost of Goods Sold, Gross Profit and Gross Margin


	Three months ended
	March 31,						Change
($ in thousands, except percentages)	2025			2024			Amount		%
Cost of product revenue	$	4,491		$	6,723		$	(2,232)	(33)	%
Cost of service and other revenue		2,277			3,248			(971)	(30)	%
Total cost of goods sold	$	6,768		$	9,971		$	(3,203)	(32)	%
Gross profit	$	9,871		$	8,379		$	1,492	18	%
Gross margin		59	%		46	%

Cost of product revenue decreased by $2.2 million, or 33%, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease in cost of product revenue was primarily due to a $2.0 million charge recorded in the first quarter of 2024 related to obsolete inventory associated with the Mantra 2 Quantitative Pathology Workstation and the Vectra 3 Automated Quantitative Pathology Imaging System (collectively, the “Discontinued Products”), a legacy product line which was discontinued in the first quarter of 2024 and decrease in costs associated with decreased instrument sales, offset by costs associated with increased reagents sales. Cost of service and other revenue decreased by $1.0 million, or 30%, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease in cost of service and other revenue was primarily driven by a decrease in personnel-related expenses due to the workforce reductions that we executed in January and July of 2024.

Gross profit decreased by $1.5 million, or 18%, and gross margin increased by 13% for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to the charge recorded in the first quarter of 2024 related to the Discontinued Products, as well as a decrease in instrument sales. The increase in gross margin was primarily due to the charge resulting from the Discontinued Products during the three months ended March 31, 2024.

Operating Expenses

Selling, General and Administrative


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Selling, general and administrative	$	17,580	$	19,863	$	(2,283)	(11)	%

Selling, general and administrative expense decreased by $2.3 million, or 11%, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease was primarily due to a $3.4 million decrease in personnel-related expenses, primarily due to the workforce reductions in January and July of 2024, a $0.5 million decrease in rent, net of sublease income, due to exiting our Menlo Park facility in the first quarter of 2024, a $0.3 million decrease in charges to our allowance for credit losses, and a $0.3 million decrease in recruiting, training, conferences, and travel and expenses, offset by a $2.6 million increase in professional fees in connection with the Merger.

Table of Contents

Research and development


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Research and development	$	5,557	$	5,554	$	3	0	%

Research and development expense increased by $3.0 thousand, or 0%, for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase was primarily due to a $0.9 million increase in consulting, engineering, and lab supply consumption, partially offset by a $0.8 million decrease in personnel-related expenses, primarily due to the workforce reductions in January and July of 2024, and other immaterial changes.

Change in fair value of contingent consideration


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Change in fair value of contingent consideration	$	146	$	179	$	(33)	(18)	%

Change in fair value of contingent consideration was a $0.1 million loss for the three months ended March 31, 2025, compared to a $0.2 million loss for the three months ended March 31, 2024. The change in fair value of $33.0 thousand, or 18%, was due to current period remeasurement.

Impairment


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Impairment	$	—	$	2,971	$	(2,971)	(100)	%

Impairment decreased by $3.0 million, or 100% for the three months ended March 31, 2025, compared to the three months ended March 31, 2024, due to impairment charges to our right-of-use assets and property and equipment associated with exiting our Menlo Park, California facilities that were recorded in the first quarter of 2024.

Restructuring


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Restructuring	$	—	$	1,397	$	(1,397)	(100)	%

Restructuring decreased by $1.4 million, or 100% for the three months ended March 31, 2025, compared to the three months ended March 31, 2024, due to the workforce reductions that we executed in January of 2024.

Interest expense


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Interest expense	$	2,492	$	2,612	$	(120)	(5)	%

Interest expense decreased by $0.1 million, or 5% for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease was due to a decrease in interest rates.

Table of Contents

Interest income


	Three months ended
	March 31,				Change
($ in thousands, except percentages)	2025		2024		Amount		%
Interest income	$	313	$	937	$	(624)	(67)	%

Interest income decreased by $0.6 million, or 67% for the three months ended March 31, 2025, compared to the three months ended March 31, 2024 due to decreased levels of cash, cash equivalents, and marketable securities as of March 31, 2025 as compared to March 31, 2024.

Other expense, net

Three months ended

March 31,

Change

($ in thousands, except percentages)

2025

2024

Amount

Other expense, net

Akoya Biosciences, Inc. 10-Q